SCHEMBL205107

SCHEMBL205107

N#Cc1cccc(Nc2nc(-c3ccc(Cl)c(Cl)c3)cs2)c1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CFTR P13569 3/20 0.65
ALOX5 P09917 4/20 0.60
VCP P55072 3/20 0.60
CYP1A1 P04798 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP1B1 Q16678 1/20 0.53
ABL1 P00519 4/20 0.52
EIF4E P06730 1/20 0.52
PTGS2 P35354 1/20 0.50
MAPT P10636 2/20 0.49
KDM4E B2RXH2 1/20 0.49
POLB P06746 1/20 0.49
GAA P10253 1/20 0.49
RECQL P46063 1/20 0.49
BLM P54132 1/20 0.49
GLA P06280 1/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207590 0.88 ALOX5 (0.68) CFTRALOX5VCPPTGS2MAPT
SCHEMBL23539305 0.87 CFTR (0.65) CFTRALOX5VCPCYP1A1CYP1A2
SCHEMBL208320 0.87 VCP (0.71) CFTRALOX5VCPABL1EIF4E
SCHEMBL12298023 0.87 CFTR (0.74) CFTRALOX5VCPCYP1A1CYP1A2
SCHEMBL14458161 0.85 CSNK2A1 (0.64) CFTRALOX5VCPCYP1A1CYP1A2
SCHEMBL6155931 0.84 VCP (0.67) CFTRALOX5VCPABL1PTGS2
SCHEMBL208940 0.83 NPY5R (0.66) CFTRALOX5VCPCYP1A1CYP1A2
SCHEMBL1885926 0.83 MAPT (0.68) CFTRALOX5VCPCYP1A1CYP1A2
SCHEMBL205976 0.82 ALOX5 (0.80) CFTRALOX5VCPABL1PTGS2
SCHEMBL6153406 0.82 CFTR (0.69) CFTRALOX5VCPABL1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 CFTR 111/4885ALOX5 3410/4885VCP 1270/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 CFTR 111/4885ALOX5 3410/4885VCP 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.